Theralase Technologies Inc. V.TLT

Valuation of the anti-virus platform

[ScienceFirst]

Valuation of a anti-virus platform, considering this:

- we have proof-of-concept data conducted by PHAC’s National Microbiology Laboratory regarding the destruction of viruses, including: H1N1 Influenza, Zika and a Biological Safety Level (“BSL”)-2 coronavirus at low nanomolar (“nM”) concentrations. These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus.

_______________________

livermore2 - (9/13/2021 7:58:01 PM)

Who saw the news on Providence Therapeutics today

Sold COVID vaccine license for estimated 500M deal - 100M cash up front!!!


More on that deal, to be able to provide a potential valuation to TLT's anti-virus platform:

Sept. 13, 2021:

Providence Therapeutics Enters into Comprehensive Agreements with Everest Medicines to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Emerging Markets in Asia - Providence Therapeutics

 

• Providence and Everest enter into a 50/50 worldwide collaboration to jointly develop products in two additional indications, leveraging Providence’s cutting-edge mRNA technology
• Providence will receive $100 million USD upfront, up to 12% equity position in Everest based upon milestones, and future profit share and royalties

Transaction Terms

Under the terms of the transaction Agreements, Providence will receive the following considerations;

For COVID-19 vaccines:

• US$50 million in initial upfront payment to be paid in cash;

• In China and Singapore, up to US$100 million in profit-sharing on COVID-19 vaccines, and once profit share has reached an aggregate amount of US$100 million, mid to high single-digit royalties, and in Everest Territories outside of China and Singapore, mid-teens royalties on COVID-19 vaccine sales.

For Collaboration Products, Additional Products, and the mRNA technology platform:

• US$50 million in initial upfront payment to be paid in cash;

• Up to US$300 million in future milestone payments to be paid in newly-issued Everest stock, based on the achievement of certain technology transfer, manufacturing, preclinical, development and commercial milestones.

Sept. 14, 2021

Emergent Biosolutions Secures Multi-year Development and Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B - Providence Therapeutics

The biotech has received some funding from the Canadian government as well as upfront payments from its Indian partner Biological E Limited. and Chinese partner Everest Medicines Limited. It now plans to seek a further $400m in funding, CEO Brad Sorenson tells Scrip in this audio interview.

Along with Biological E and its North American partners - Emergent BioSolutions, Inc. and Northern Therapeutics Inc.- Providence aims to produce 1-1.5 billion doses of its coronavirus vaccines.

In the interview, Sorenson also discusses vaccines against cancer that are part of Providence Therapeutics’ suite of mRNA products.

 

[Mongoose1975]

I'm almost more excited about this over our Cancer fighting drug. ALMOST. Right now the MrNA vaccines only give a high rate of protection and will continue to need boosters moving forward. They do Not and were never promised to keep people from catching COVID. I've been watching the numbers of hospitalizations and the ratio between vaccinated and none vaccinated and it looks to be almost

[ScienceFirst]

COVID-19 doesn't go away.  We might find an interested partner.   March 30 - Experts say Quebec has entered a sixth wave of COVID-19 propelled by BA.2 subvariant   March 30 - US Senate scrambles to reach 15B$ funding deal for Covid vaccines, testing and treatment   The party is pushing for a quick deal, saying that any gap in funding would put the

[ScienceFirst]

1 day ago -  Ontario has entered the sixth COVID-19 wave, doctors say Ontario reported a more than +23% week-over-week increase in COVID-19 hospitalizations on Tuesday as one epidemiologist says the province is now in a sixth wave of the pandemic.  The Ministry of Health says there are currently 790 patients with the virus in Ontario hospitals, compared to 639 a week ago. 1 day ago